Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TQB2450 Combined With AL2846 in Advanced Solid Tumors
NCT06116240Phase 1Active, not recruiting
- Sponsor
- Chia Tai-Tianqing Pharmaceutical Group
- Start
- Sep 2022
- Primary completion
- Dec 2023
- Modality
- Small Molecules, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label trial of benmelstobart and vilzemetkib in hepatocellular carcinoma (HCC), gastric adenocarcinoma, non-small cell lung cancer (NSCLC) and 2 more (6 arms), sponsored by Chia Tai-Tianqing Pharmaceutical Group. Primary endpoint: Objective Response Rate. Started Sep 2022; status: active, not recruiting.
02
Drugs
benmelstobartvilzemetkib
03
Conditions
hepatocellular carcinoma (HCC)gastric adenocarcinomanon-small cell lung cancer (NSCLC)urothelial carcinoma (UC)Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on NCT06116240.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06116240.